News &amp; Updates

Patients with chronic hepatitis B (CHB) in the indeterminate phase are predisposed to advanced liver disease and hepatocellular carcinoma (HCC), as shown by a systematic review and meta-analysis.

Antiviral therapy lowers HCC risk in indeterminate CHB phase

27 May 2025

Women with past hypertensive pregnancy at greater CV risk

Blood pressure values and ventricular mass tend to be more elevated among women with previous de novo pre-eclampsia (PE) than those with previous normal pregnancies, according to a study.

Women with past hypertensive pregnancy at greater CV risk

FMT bodes well for AMR

The PROFIT trial turns waste into gains by showing how faecal microbiota transplantation (FMT) can combat antimicrobial resistance (AMR) in patients with liver cirrhosis.

FMT bodes well for AMR

MRI better at predicting long-term structural damage in early RA

In patients with early rheumatoid arthritis (RA), baseline MRI of the wrist is better than clinical, serological, or radiographic assessment at predicting long-term structural damage, an 8-year longitudinal study by researchers from the Chinese University of Hong Kong (CUHK) has shown.

MRI better at predicting long-term structural damage in early RA

27 May 2025

$Testosterone offers no long-distance mobility benefit to women with hip fracture$

Testosterone offers no long-distance mobility benefit to women with hip fracture

Use of topical testosterone therapy in addition to supervised exercise training does little to improve long-distance walking ability for older women recovering from a hip fracture, according to the phase III STEP-HI randomized clinical trial.

Testosterone offers no long-distance mobility benefit to women with hip fracture

Seladelpar improves cholestatic, liver injury markers in patients with PBC, cirrhosis

Treatment with seladelpar led to improvements in markers of cholestasis and liver injury in patients with primary biliary cholangitis (PBC) and compensated cirrhosis, according to an additional analysis of the RESPONSE trial presented at DDW 2025.

Seladelpar improves cholestatic, liver injury markers in patients with PBC, cirrhosis

Etrasimod shows promise in eosinophilic oesophagitis

In the treatment of eosinophilic oesophagitis, the use of etrasimod is well tolerated and results in sustained histological and endoscopic improvements and symptom reduction, according to the results of a phase II study.

Etrasimod shows promise in eosinophilic oesophagitis

Superior IBD control achieved with biomarker-guided therapy standard care

26 May 2025 by

Biomarker-informed molecular guidance improves anti-TNF therapy outcomes in patients with inflammatory bowel disease (IBD), increasing the likelihood of achieving disease control when compared with standard “best care,” as shown in the GUIDE-IBD trial.

Superior IBD control achieved with biomarker-guided therapy standard care

26 May 2025

Monitor kidney function to reduce CV risk in CKD patients: study

In patients with stable chronic kidney disease (CKD), the risk of cardiomyopathy caused by kidney disease appears to be greater than the risk of CKD progression due to heart disease, suggests a study, noting that these observational analyses do not establish causality.

Monitor kidney function to reduce CV risk in CKD patients: study

High, increasing BMI ups risk of adulthood OSA

26 May 2025 by

Individuals with high or continuously increasing BMI from childhood to middle age are at greater risk of developing obstructive sleep apnoea (OSA) later in life, reveals a study.

High, increasing BMI ups risk of adulthood OSA